Stevens Institute of Technology
United States of America
Dr. Paliwal has 15 years experience as a medicinal chemist and project leader performing research in drug discovery for Schering-Plough Research Institute and at Merck where he was Director of Exploratory Medicinal Chemistry. His expertise is in developing small molecules to treat oncology, neurological, cardiovascular and inflammation diseases. Dr. Paliwal’s preclinical discovery includes leading teams to discover early drug hits from high-throughput screening (HTS) involving the screening of millions of compounds, optimization of hits and developing program leads through evaluations of chemical structure and biological data to develop key structural-activity-relationships (SAR). Dr. Paliwal’s research experience also include optimization of the DMPK and biological data of the leads to deliver clinical compounds with optimal DMPK/pharmacological properties. He is co-inventor of a drug (Varubi®) and has progressed two other compounds into clinic to treat cancer and neurological diseases.
Developing molecules to treat cancer and also developing selective chemical probes for validation of novel targets..
Paliwal S, Reichard GA, Shah S, Wrobleski ML, Wang C, et al. (2008) Discovery of a novel, potent and orally active series of γ-lactams as selective NK 1 antagonists. Bioorganic & medicinal chemistry letters 18: 4168-4171.